Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)

NCT02553642 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

81

Enrollment

OTHER

Sponsor class

Conditions

Bladder Cancer
Melanoma

Interventions

DRUG: Nivolumab
DRUG: Nivolumab plus Ipilimumab

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]